Canntab Therapeutics Ltd
CNSX:PILL
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
C
|
Canntab Therapeutics Ltd
CNSX:PILL
|
194.5k CAD |
Loading...
|
|
| IN |
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
4.3T INR |
Loading...
|
|
| CH |
S
|
Sandoz Group AG
SIX:SDZ
|
26.9B CHF |
Loading...
|
|
| US |
|
Dupont De Nemours Inc
NYSE:DD
|
18.6B USD |
Loading...
|
|
| CN |
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
111B CNY |
Loading...
|
|
| CN |
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
44.2B CNY |
Loading...
|
|
| CN |
|
Hebei Changshan Biochemical Pharmaceutical Co Ltd
SZSE:300255
|
39.4B CNY |
Loading...
|
|
| US |
|
Balchem Corp
NASDAQ:BCPC
|
5.6B USD |
Loading...
|
|
| CN |
C
|
Changchun High & New Technology Industries Group Inc
SZSE:000661
|
37.1B CNY |
Loading...
|
|
| UK |
|
Croda International PLC
LSE:CRDA
|
3.8B GBP |
Loading...
|
|
| JP |
|
Sumitomo Pharma Co Ltd
TSE:4506
|
746.3B JPY |
Loading...
|
Market Distribution
| Min | -10 058.3% |
| 30th Percentile | 20.4% |
| Median | 33.6% |
| 70th Percentile | 50.5% |
| Max | 717.4% |
Other Profitability Ratios
Canntab Therapeutics Ltd
Glance View
Canntab Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-04-21. The firm is focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The firm operates in one reportable operating, being engaged in the medical marijuana business. All property and equipment, right-of-use assets and intangible assets are located in Canada. Its hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet. The company holds cannabis standard processing and sales for medical purposes license, a cannabis research license, and an industrial hemp license from health Canada.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Canntab Therapeutics Ltd is -43.9%, which is in line with its 3-year median of -43.9%.
Over the last 2 years, Canntab Therapeutics Ltd’s Gross Margin has decreased from 24.2% to -43.9%. During this period, it reached a low of -43.9% on Feb 28, 2023 and a high of 48.8% on Feb 28, 2022.
